Hillstream BioPharma, Inc. - HILS STOCK NEWS

Hillstream BioPharma, Inc. (Nasdaq: HILS) has partnered with OncoBay Clinical to support the clinical development of HSB-1216, its lead drug candidate targeting drug-resistant cancers via ferroptosis. The collaboration aims to utilize OncoBay’s expertise in clinical and regulatory support, which includes data management and statistical programming. Hillstream anticipates submitting an investigational new drug application and commencing clinical studies in the second half of 2023. The partnership is expected to accelerate the development of HSB-1216, which aims to leverage iron-mediated cell death to combat challenging cancers. Hillstream's pipeline also includes HSB-3215, a novel anti-HER2 monoclonal antibody. Hillstream believes that the extensive oncological expertise of OncoBay and its ties to Moffitt Cancer Center position the partnership for success.

Hillstream Biopharma is capitalizing on the rapid growth of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to exceed $581.25 billion by 2030, growing at a CAGR of 8.2% from 2022 to 2030. The company is advancing its lead drug candidate, HSB-1216, designed to target solid tumors through ferroptosis, which is the first of its kind. Utilizing the proprietary Quatramer platform, HSB-1216 aims to minimize off-target toxicity while effectively treating cancers like triple-negative breast cancer. Early preclinical results have been promising, indicating its potential to transform cancer treatment. CEO Randy Milby, an experienced industry leader, is spearheading this innovation, marking a significant step forward in the quest for effective cancer therapies.

Hillstream BioPharma (Nasdaq: HILS) announced positive pharmacokinetic (PK) data for its drug candidate HSB-1216, highlighting its potential in targeting drug-resistant cancers. The recent IND-enabling studies demonstrated that the Quatramer™ technology effectively protected HSB-1216 from metabolic degradation, ensuring its release directly at tumor sites, consistent with previous pre-clinical results indicating tumor growth reduction.

The studies showed promising preliminary safety and PK profiles in both rats and dogs, supporting Hillstream's ongoing development strategy. The company plans to submit an investigational new drug application for HSB-1216 in the second half of 2023, aiming to target ferroptosis, a novel anti-cancer mechanism.

Hillstream BioPharma (Nasdaq: HILS) announced participation in two significant industry conferences in April 2023. The BioNJ BioPartnering Conference will be held on April 17-18 in Somerset, NJ, and the CPHI North America Conference on April 25-27 in Philadelphia, PA. CEO Randy Milby will present and conduct one-on-one meetings with analysts and investors at both events, discussing operational highlights and pipeline candidates, including HSB-1216 and HSB-3215. Both conferences aim to foster collaboration and innovation in the pharmaceutical sector.

Hillstream BioPharma, Inc. (Nasdaq: HILS) has announced its participation in the 35th Annual Roth Conference from March 12-14, 2023, at The Ritz-Carlton Hotel, California. The company will hold one-on-one meetings with institutional investors and analysts, showcasing its investment thesis and therapeutic candidates targeting drug-resistant cancers through innovative mechanisms like ferroptosis. Recently, Hillstream signed an exclusive option agreement with Applied Biomedical Science Institute to license technology for HER2 and HER3. The CEO expressed eagerness for the conference, highlighting its significance for networking and investment opportunities.

Hillstream BioPharma (Nasdaq: HILS) has regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of over $1.00 for ten consecutive trading days as of February 13, 2023. The company held a virtual R&D Day on February 14, discussing its four pipeline candidates and recent agreements, including an exclusive option with Applied Biomedical Science Institute for HER2 and HER3 technologies targeting drug-resistant cancers. Additionally, a preclinical study of HSB-1216, in combination with pembrolizumab, showed positive results against KRAS-G12C-mutated non-small cell lung cancer cells. The oncology market is projected to reach $11 billion by 2028.

Hillstream BioPharma has signed an exclusive option agreement with the Applied Biomedical Science Institute to license technology aimed at drug-resistant cancers, including HER2-positive metastatic breast cancer and others. The company is focused on developing therapeutic candidates that utilize ferroptosis, a novel anti-cancer mechanism. Recent preclinical studies of HSB-1216 showed significant tumor inhibition when combined with pembrolizumab against KRAS G12C-mutated non-small cell lung cancer cells. Hillstream aims to address key oncology markets projected to reach $11 billion by 2028 and will host a virtual R&D Day on February 14, 2023.